Given this limited success of the ABCG2 inhibitor Ko143, we tested EZN-2208, a pegylated form of the active irinotecan metabolite SN38 [28], to treat ABCG2-positive Brca1−/−;p53−/− mammary tumors. Here, BRCA1 is linked to breast cancer.